MedTrace Logo

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

NCT02930018 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1105

Last updated 2022-10-10

Study results available
· View outcomes & findings →

Summary

The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization.

Conditions

  • Stroke, Acute

Interventions

DRUG

Nerinetide (NA-1), 2.6 mg/kg

Single intravenous infusion of nerinetide over 10 ± 1 minutes

DRUG

Placebo

Placebo Comparator: Placebo

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • NoNO Inc.

    lead INDUSTRY

Principal Investigators

  • Michael D Hill, MD MSc · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2019-11-20
Completion
2019-11-20
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Ireland
  • South Korea
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02930018 on ClinicalTrials.gov